标题
Clinical Pharmacokinetics and Pharmacodynamics of Afatinib
作者
关键词
Epidermal Growth Factor Receptor, Ritonavir, Epidermal Growth Factor Receptor Mutation, Advanced Solid Tumour, Drug Interaction Study
出版物
CLINICAL PHARMACOKINETICS
Volume 56, Issue 3, Pages 235-250
出版商
Springer Nature
发表日期
2016-07-28
DOI
10.1007/s40262-016-0440-1
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- 1248PA PHASE IB OPEN LABEL CLINICAL TRIAL OF CONTINUOUS ONCE DAILY ORAL AFATINIB (A) PLUS SIROLIMUS (S) IN PATIENTS (PTS) WITH EGFR MUTATION POSITIVE (EGFR M+) NSCLC AND/OR DISEASE PROGRESSION FOLLOWING PRIOR ERLOTINIB (E) OR GEFITINIB (G)
- (2017) T. Moran et al. ANNALS OF ONCOLOGY
- Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study
- (2016) Sabrina Wiebe et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole
- (2016) Katharina Gunzer et al. SpringerPlus
- Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer
- (2015) Hirofumi Mukai et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours
- (2015) A. Suder et al. EUROPEAN JOURNAL OF CANCER
- A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors
- (2015) Michael S Gordon et al. Future Oncology
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
- (2015) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
- (2015) Jean-Charles Soria et al. LANCET ONCOLOGY
- Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors
- (2014) Matthias Freiwald et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
- (2014) David Schnell et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer
- (2014) A. Ring et al. CLINICAL CANCER RESEARCH
- Pharmacokinetic Drug Interactions of Afatinib with Rifampicin and Ritonavir
- (2014) Sven Wind et al. CLINICAL DRUG INVESTIGATION
- A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors
- (2014) Quincy S. Chu et al. INVESTIGATIONAL NEW DRUGS
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer
- (2014) Helmout Modjtahedi et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors
- (2013) J. B. Vermorken et al. ANNALS OF ONCOLOGY
- Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors
- (2013) L. Rhoda Molife et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
- (2013) H. A. Yu et al. CLINICAL CANCER RESEARCH
- Pharmacokinetics of Afatinib, a Selective Irreversible ErbB Family Blocker, in Patients with Advanced Solid Tumours
- (2013) Sven Wind et al. CLINICAL PHARMACOKINETICS
- LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both
- (2013) Nobuyuki Katakami et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
- (2012) Nancy U. Lin et al. BREAST CANCER RESEARCH AND TREATMENT
- A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
- (2012) Michael S. Gordon et al. INVESTIGATIONAL NEW DRUGS
- Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors
- (2012) A. H. Awada et al. INVESTIGATIONAL NEW DRUGS
- A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors
- (2012) John Marshall et al. INVESTIGATIONAL NEW DRUGS
- Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
- (2012) Vincent A Miller et al. LANCET ONCOLOGY
- Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
- (2012) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Effects of Tobacco Smoking and Nicotine on Cancer Treatment
- (2012) William P. Petros et al. PHARMACOTHERAPY
- Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers
- (2011) Peter Stopfer et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4)
- (2011) H. Murakami et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- Treatment of lung cancer patients and concomitant use of drugs interacting with cytochrome P450 isoenzymes
- (2011) Xue Song et al. LUNG CANCER
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors
- (2010) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Method for predicting the risk of drug–drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein
- (2009) T. Tachibana et al. XENOBIOTICA
- Emerging Evidence of the Impact of Kidney Disease on Drug Metabolism and Transport
- (2008) TD Nolin et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Assessment of the Impact of Renal Impairment on Systemic Exposure of New Molecular Entities: Evaluation of Recent New Drug Applications
- (2008) Y Zhang et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- EGFR Antagonists in Cancer Treatment
- (2008) Fortunato Ciardiello et al. NEW ENGLAND JOURNAL OF MEDICINE
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
- (2008) C.-H. Yun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started